Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis

American Journal of Kidney Diseases

Volumn 46, Issue 1, 2005, Pages 58-67

  Charytan, Chaim ^a   Coburn, Jack W ^b   Chonchol, Michel ^b   Herman, James ^b   Lien, Y Howard ^b   Liu, Wei ^b   Klassen, Preston S ^b   McCary, Laura C ^b   Pichette, Vincent ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b NONE

Author keywords

Calcimimetic; Chronic kidney disease (CKD); Hyperparathyroidism; Predialysis

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MYALGIA; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TITRIMETRY; VITAMIN SUPPLEMENTATION;

CALCIUM; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; TREATMENT OUTCOME; VITAMIN D;

EID: 20744432055     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2005.04.013     Document Type: Article

References (38)

1. I. Martinez, R. Saracho, J. Montenegro, F. Llach The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure Am J Kidney Dis 29 1997 496 502
2. E. Slatopolsky, A. Brown, A. Dusso Role of phosphorus in the pathogenesis of secondary hyperparathyroidism Am J Kidney Dis 37 suppl 2 2001 S54 S57
3. T.B. Drueke The pathogenesis of parathyroid gland hyperplasia in chronic renal failure Kidney Int 48 1995 259 272
4. G. Coen, S. Mazzaferro, P. Ballanti Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure A cross-sectional study Nephrol Dial Transplant 11 1996 813 819
5. T. Cundy, D.J. Hand, D.O. Oliver, C.G. Woods, F.W. Wright, J.A. Kanis Who gets renal bone disease before beginning dialysis? Br Med J 290 1985 271 275
6. G.B. Spasovski, A.R. Bervoets, G.J. Behets Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis Nephrol Dial Transplant 18 2003 1159 1166
7. A.M. Parfitt The actions of parathyroid hormone on bone: Relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV: The state of the bones in uremic hyperparathyroidism - The mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis Metabolism 25 1976 1157 1188
8. S.C. Manolagas Birth and death of bone cells Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr Rev 21 2000 115 137
9. G. Block, P. Raggi, R. Mehta Cardiovascular calcification in new hemodialysis patients Assessment with electron beam computed tomography Hemodial Int 8 2004 265 272
10. Y. Leskinen, T. Lehtimaki, A. Loimaala Carotid atherosclerosis in chronic renal failure - The central role of increased plaque burden Atherosclerosis 171 2003 295 302
11. T. Shoji, M. Emoto, T. Tabata Advanced atherosclerosis in predialysis patients with chronic renal failure Kidney Int 61 2002 2187 2192
12. G.A. Block, T.E. Hulbert-Shearon, N.W. Levin, F.K. Port Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients A national study Am J Kidney Dis 31 1998 607 617
13. G.A. Block, P.S. Klassen, J.M. Lazarus, N. Ofsthun, E.G. Lowrie, G.M. Chertow Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 2004 2208 2218
14. S.K. Ganesh, A.G. Stack, N.W. Levin, T. Hulbert-Shearon, F.K. Port Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients J Am Soc Nephrol 12 2001 2131 2138
15. W.G. Goodman, G. London, K. Amann Vascular calcification in chronic kidney disease Am J Kidney Dis 43 2004 572 579
16. M.P. Marco, L. Craver, A. Betriu, M. Belart, J. Fibla, E. Fernandez Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population Kidney Int Suppl 85 2003 S111 S114
17. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease Am J Kidney Dis 42 suppl 3 2003 S1 S201
18. E.M. Brown, R.J. MacLeod Extracellular calcium sensing and extracellular calcium signaling Physiol Rev 81 2001 239 297
19. E.F. Nemeth, W.H. Heaton, M. Miller Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl J Pharmacol Exp Ther 308 2004 627 635
20. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568 Mol Pharmacol 53 1998 1083 1088
21. M. Wada, N. Nagano, Y. Furuya, J. Chin, E.F. Nemeth, J. Fox Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism Kidney Int 57 2000 50 58
22. E.F. Nemeth, M.E. Steffey, L.G. Hammerland Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc Natl Acad Sci U S A 95 1998 4040 4045
23. J. Silver, J. Russell, L.M. Sherwood Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells Proc Natl Acad Sci U S A 82 1985 4270 4273
24. J. Silver, C. Yalcindag, A. Sela-Brown, R. Kilav, T. Naveh-Many Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate Kidney Int Suppl 73 1999 S2 S7
25. G.A. Block, K.J. Martin, A.L. de Francisco Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 2004 1516 1525
26. W.G. Goodman, G.A. Hladik, S.A. Turner The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism J Am Soc Nephrol 13 2002 1017 1024
27. J.S. Lindberg, B. Culleton, G. Wong Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis A randomized, double-blind, multicenter study J Am Soc Nephrol 16 2005 800 807
28. J.S. Lindberg, S.M. Moe, W.G. Goodman The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism Kidney Int 63 2003 248 254
29. L.D. Quarles, D.J. Sherrard, S. Adler The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease J Am Soc Nephrol 14 2003 575 583
30. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, D. Roth Modification of Diet in Renal Disease Study Group A more accurate method to estimate glomerular filtration rate from serum creatinine A new prediction equation Ann Intern Med 130 1999 461 470
31. S.R. Nussbaum, R.J. Zahradnik, J.R. Lavigne Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia Clin Chem 33 1987 1364 1367
32. A.T. Kausz, S.S. Khan, R. Abichandani Management of patients with chronic renal insufficiency in the northeastern United States J Am Soc Nephrol 12 2001 1501 1507
33. I.H. De Boer, I. Gorodetskaya, B. Young, C.Y. Hsu, G.M. Chertow The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease J Am Soc Nephrol 13 2002 2762 2769
34. M. Chonchol, N. Kopyt, J. Herman Cinacalcet HCl reduces parathyroid hormone (PTH) in patients with stage 3 and 4 chronic kidney disease (CKD) Am J Kidney Dis 43 2004 19A (abstr)
35. K.J. Martin, K. Olgaard, J.W. Coburn Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy Am J Kidney Dis 43 2004 558 565
36. E. Slatopolsky, A. Brown, A. Dusso Pathogenesis of secondary hyperparathyroidism Kidney Int Suppl 73 1999 S14 S19
37. M. Wada, Y. Furuya, J. Sakiyama The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor J Clin Invest 100 1997 2977 2983
38. M. Wada, Y. Furuya, N. Kobayashi The Calcimimetic Compound, Cinacalcet HCl, Ameliorates Osteitis Fibrosa in Rats With Chronic Renal Insufficiency J Bone Miner Res 18 suppl 2 2003 S99